1
项与 NYK-1001(Chaperone Pharma BV) 相关的临床试验 / Active, not recruiting临床1/2期IIT A Phase Ib/II Trial of Combined SGN-35 (BrentuximabVedotin) Therapy With Cyclophosphamide, Procarbazine, Prednisone, Etoposide and Mitoxantrone (BrEPEM) for Older Patients With Untreated Hodgkin Lymphoma (HL)
The purpose of the phase Ib of the study is to identify the maximum tolerated dose (MTD) of Brentuximab Vedotin (BV) in combination with EPEM and to assess the toxicity of the combination of BV with EPEM. In the phase II efficacy will be evaluated.Besides, progression-free survival (PFS), event-free survival (EFS), overall survival (OS), the duration of response, the overall response rate (ORR) based on best response will be evaluated
100 项与 NYK-1001(Chaperone Pharma BV) 相关的临床结果
100 项与 NYK-1001(Chaperone Pharma BV) 相关的转化医学
100 项与 NYK-1001(Chaperone Pharma BV) 相关的专利(医药)
100 项与 NYK-1001(Chaperone Pharma BV) 相关的药物交易